Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Egan, Karl ^a   Crowley, Darragh ^b   Smyth, Paul ^b   O'Toole, Sharon ^b   Spillane, Cathy ^b   Martin, Cara ^b   Gallagher, Michael ^b   Canney, Aoife ^b   Norris, Lucy ^b   Conlon, Niamh ^b   McEvoy, Lynda ^b   Ffrench, Brendan ^b   Stordal, Britta ^b   Keegan, Helen ^b   Finn, Stephen ^b   McEneaney, Victoria ^b   Laios, Alex ^b   Ducrée, Jens ^c   Dunne, Eimear ^a   Smith, Leila ^d   Berndt, Michael ^a,c   Sheils, Orla ^b   Kenny, Dermot ^a,c   O'Leary, John ^b   more..

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c DUBLIN CITY UNIVERSITY   (Ireland)

^d Fluidigm Corporation [Europe   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; COLLAGEN; PADGEM PROTEIN; PROTEINASE ACTIVATED RECEPTOR 4; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; THROMBOXANE A2; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; APYRASE; ARACHIDONIC ACID; CANGRELOR; DRUG DERIVATIVE; N(6) METHYL 2' DEOXYADENOSINE 3',5' DIPHOSPHATE; N(6)-METHYL-2'-DEOXYADENOSINE 3',5'-DIPHOSPHATE; PEPTIDE FRAGMENT; PROTEASE-ACTIVATED RECEPTOR 4; THROMBIN RECEPTOR; THROMBIN RECEPTOR PEPTIDE SFLLRNP;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CELL; CELL SURVIVAL; CONTROLLED STUDY; DEGRANULATION; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; OVARY CANCER; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; DNA MICROARRAY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); OVARY TUMOR; PATHOLOGY; REPRODUCIBILITY; SIGNAL TRANSDUCTION; THROMBOCYTE ADHESIVENESS; VASCULARIZATION;

ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; ADENOSINE TRIPHOSPHATE; APYRASE; ARACHIDONIC ACID; CELL DEGRANULATION; CELL SURVIVAL; DRUG SYNERGISM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; PLATELET ADHESIVENESS; RECEPTORS, PURINERGIC P2Y1; RECEPTORS, PURINERGIC P2Y12; RECEPTORS, THROMBIN; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION;

EID: 80054005719     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026125     Document Type: Article

References (52)

1. Landen CN, Birrer MJ, Sood AK, (2008) Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26: 995-1005.
2. Holschneider CH, Berek JS, (2000) Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19: 3-10.
3. Naora H, Montell DJ, (2005) Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 5: 355-66.
4. Dvoretsky PM, Richards KA, Angel C, Rabinowitz L, Stoler MH, et al. (1988) Distribution of disease at autopsy in 100 women with ovarian cancer. Hum Pathol 19: 57-63.
5. Braun S, Schindlbeck C, Hepp F, Janni W, Kentenich C, et al. (2001) Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse. J Clin Oncol 19: 368-75.
6. Gasic GJ, Gasic TB, Stewart CC, (1968) Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A 61: 46-52.
7. Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, et al. (2004) Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 104: 397-401.
8. Jain S, Russell S, Ware J, (2009) Platelet glycoprotein VI facilitates experimental lung metastasis in syngenic mouse models. J Thromb Haemost 7: 1713-7.
9. Jain S, Zuka M, Liu J, Russell S, Dent J, et al. (2007) Platelet glycoprotein Ib alpha supports experimental lung metastasis. Proc Natl Acad Sci U S A 104: 9024-8.
10. Kim YJ, Borsig L, Varki NM, Varki A, (1998) P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci U S A 95: 9325-30.
11. Philippe C, Philippe B, Fouqueray B, Perez J, Lebret M, et al. (1993) Protection from tumor necrosis factor-mediated cytolysis by platelets. Am J Pathol 143: 1713-23.
12. Nieswandt B, Hafner M, Echtenacher B, Männel DN, (1999) Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 59: 1295-300.
13. Maloney JP, Silliman CC, Ambruso DR, Wang J, Tuder RM, et al. (1998) In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol 275: H1054-61.
14. Gungor T, Kanat-Pektas M, Sucak A, Mollamahmutoglu L, (2009) The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors. Arch Gynecol Obstet 279: 53-6.
15. Iodice S, Gandini S, Löhr M, Lowenfels AB, Maisonneuve P, (2008) Venous thromboembolic events and organ-specific occult cancers: a review and meta-analysis. J Thromb Haemost 6: 781-8.
16. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, et al. (1999) Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine [Baltimore] 78: 285-91.
17. Edwards RJ, Moran N, Devocelle M, Kiernan A, Meade G, et al. (2007) Bioinformatic discovery of novel bioactive peptides. Nat Chem Biol 3: 108-12.
18. Stevens JM, (2004) Platelet adhesion assays performed under static conditions. Methods Mol Biol 272: 145-51.
19. Nylander S, Mattsson C, Ramström S, Lindahl TL, (2004) Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation. Br J Pharmacol 142: 1325-31.
20. Thomson S, Petti F, Sujka-Kwok I, Mercado P, Bean J, et al. (2011) A systems view of epithelial-mesenchymal transition signaling states. Clin Exp Metastasis 28: 137-55.
21. Medina C, Jurasz P, Santos-Martinez MJ, Jeong SS, Mitsky T, et al. (2006) Platelet aggregation-induced by caco-2 cells: regulation by matrix metalloproteinase-2 and adenosine diphosphate. J Pharmacol Exp Ther 317: 739-45.
22. Uluçkan O, Eagleton MC, Floyd DH, Morgan EA, Hirbe AC, et al. (2008) APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice. J Cell Biochem 104: 1311-23.
23. Italiano JE, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, et al. (2008) Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 111: 1227-33.
24. Bambace NM, Levis JE, Holmes CE, (2010) The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets. Platelets 21: 85-93.
25. Yousef GM, Polymeris ME, Yacoub GM, Scorilas A, Soosaipillai A, et al. (2003) Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res 63: 2223-7.
26. Zhang T, Ma Z, Wang R, Wang Y, Wang S, et al. (2010) Thrombin facilitates invasion of ovarian cancer along peritoneum by inducing monocyte differentiation toward tumor-associated macrophage-like cells. Cancer Immunol Immunother 59: 1097-108.
27. Holmes CE, Levis JE, Ornstein DL, (2009) Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis. Clin Exp Metastasis 26: 653-61.
28. Aitokallio-Tallberg AM, Viinikka LU, Ylikorkala RO, (1988) Increased synthesis of prostacyclin and thromboxane in human ovarian malignancy. Cancer Res 48: 2396-8.
29. Croucher DR, Saunders DN, Lobov S, Ranson M, (2008) Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat Rev Cancer 8: 535-45.
30. Minami SS, Sung YM, Dumanis SB, Chi SH, Burns MP, et al. (2010) The cytoplasmic adaptor protein X11alpha and extracellular matrix protein Reelin regulate ApoE receptor 2 trafficking and cell movement. FASEB J 24: 58-69.
31. Pennings MT, Derksen RH, van Lummel M, Adelmeijer J, VanHoorelbeke K, et al. (2007) Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and apolipoprotein E receptor 2′. J Thromb Haemost 5: 369-77.
32. White TC, Berny MA, Tucker EI, Urbanus RT, de Groot PG, et al. (2008) Protein C supports platelet binding and activation under flow: role of glycoprotein Ib and apolipoprotein E receptor 2. J Thromb Haemost 6: 995-1002.
33. Urbanus RT, Pennings MT, Derksen RH, de Groot PG, (2008) Platelet activation by dimeric beta2-glycoprotein I requires signaling via both glycoprotein Ibalpha and apolipoprotein E receptor 2′. J Thromb Haemost 6: 1405-12.
34. White-Adams TC, Berny MA, Tucker EI, Gertz JM, Gailani D, et al. (2009) Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2). Arterioscler Thromb Vasc Biol 29: 1602-7.
35. Coppinger JA, O'Connor R, Wynne K, Flanagan M, Sullivan M, et al. (2009) Moderation of the platelet releasate response by aspirin. Blood 109: 4786-92.
36. Yang WL, Godwin AK, Xu XX, (2004) Tumor necrosis factor-alpha-induced matrix proteolytic enzyme production and basement membrane remodeling by human ovarian surface epithelial cells: molecular basis linking ovulation and cancer risk. Cancer Res 64: 1534-40.
37. Zhang J, Patel L, Pienta KJ, (2010) Targeting Chemokine (C-C motif) Ligand 2 (CCL2) as an Example of Translation of Cancer Molecular Biology to the Clinic. Prog Mol Biol Transl Sci 95: 31-53.
38. Zhang L, Blackwell K, Altaeva A, Shi Z, Habelhah H, (2011) TRAF2 phosphorylation promotes NF-{kappa}B-dependent gene expression and inhibits oxidative stress-induced cell death. Mol Biol Cell 22: 128-40.
39. Yanagie H, Hisa T, Ono M, Eriguchi M, (2010) [Chemokine and chemokine receptor related to cancer metastasis]. Gan To Kagaku Ryoho 37: 2052-7.
40. Chandler LA, Sosnowski BA, McDonald JR, Price JE, Aukerman SL, et al. (1998) Targeting tumor cells via EGF receptors: selective toxicity of an HBEGF-toxin fusion protein. Int J Cancer 78: 106-11.
41. Mullenders J, Fabius AW, van Dongen MM, Kuiken HJ, Beijersbergen RL, et al. (2010) Interleukin-1R-associated kinase 2 is a novel modulator of the transforming growth factor beta signaling cascade. Mol Cancer Res 8: 592-603.
42. Dong H, Chen L, (2003) B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med 81: 281-7.
43. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, et al. (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793-800.
44. Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, et al. (2008) B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111: 3635-43.
45. Miesbach W, (2009) Malignancies and catastrophic anti-phospholipid syndrome. Clin Rev Allergy Immunol 36: 91-7.
46. Choi SY, Gonzalvez F, Jenkins GM, Slomianny C, Chretien D, et al. (2007) Cardiolipin deficiency releases cytochrome c from the inner mitochondrial membrane and accelerates stimuli-elicited apoptosis. Cell Death Differ 14: 597-606.
47. Schlumbrecht MP, Xie SS, Shipley GL, Urbauer DL, Broaddus RR, (2010) Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum. Mod Pathol 24: 453-62.
48. Deng L, Feng J, Broaddus R, (2010) The novel estrogen-induced gene EIG121 regulates autophagy and promotes cell survival under stress. Cell Death Dis 1: e32.
49. Avgeris M, Mavridis K, Scorilas A, (2010) Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biol Chem 391: 505-11.
50. Prezas P, Arlt MJ, Viktorov P, Soosaipillai A, Holzscheiter L, et al. (2006) Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells. Biol Chem 387: 807-11.
51. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, et al. (2009) Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 11: R46.
52. Bonnomet A, Brysse A, Tachsidis A, Waltham M, Thompson EW, et al. (2010) Epithelial-to-mesenchymal transitions and circulating tumor cells. J Mammary Gland Biol Neoplasia 15: 261-73.